Revolution Medicines (NasdaqGS:RVMD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker15Good day, and thank you for standing by. Welcome to Revolution Medicines' fourth quarter 2025 earnings conference call. After the speaker's presentation, there will be a question-and-answer session. To ask a question during your session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 aga ...

Core Insights - Revolution Medicines, Inc. has received a non-transferrable voucher from the FDA for daraxonrasib (RMC-6236) under the Commissioner's National Priority Voucher pilot program, recognizing the unmet need for treatments for RAS-addicted cancers [1][3] - Daraxonrasib is currently being evaluated in two global Phase 3 clinical trials targeting metastatic pancreatic ductal adenocarcinoma and metastatic non-small cell lung cancer [2][5] - The company anticipates data readout from the RASolute 302 trial in 2026 and is committed to working with the FDA to expedite the drug's availability to patients [3][4] Company Overview - Revolution Medicines is focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes multiple RAS(ON) inhibitors [6] - The company's RAS(ON) inhibitors include daraxonrasib (multi-selective), elironrasib (G12C-selective), and zoldonrasib (G12D-selective), with plans for RMC-5127 (G12V-selective) to enter clinical development soon [6] - The company aims to address a wide range of cancers driven by oncogenic RAS mutations, including pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer [5][6]